46 results
8-K
EX-10.1
BFRI
Biofrontera Inc
23 Feb 24
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
9:26am
its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials
8-K
EX-10.1
BFRI
Biofrontera Inc
20 Feb 24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
9:37am
to their obligations under Section 10.1. or Section 10.5., the Transfer Price will be reduced by [***]% of net sales.
RECALL
The Parties shall:
co … .
characteristics which could impair the safety or efficacy of the Product.
Whenever a recall and/or withdrawal of Product or Lamp in Territory
8-K
BFRI
Biofrontera Inc
12 Feb 24
Other Events
9:39pm
”) was notified that its licensor for Ameluz®, Biofrontera AG (the “Licensor”), had initiated a voluntary recall of a limited number of lots of Ameluz® … of notifying all impacted physician customers of this recall and arranging for the prompt replacement of the recalled products.
Pursuant to the Company’s
8-K
EX-10.2
mxe0srj4
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
8-K
EX-10.1
3z5l iiapnpvaoixbx3w
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
424B4
xgmvrv9n6ncd
1 Nov 23
Prospectus supplement with pricing info
5:09pm
8-K
EX-10.1
ige8d28quvoan
20 May 22
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
4:30pm
424B3
yivmb2xlk0o2
8 Apr 22
Prospectus supplement
9:47pm
424B3
67xemx8 y8k94nqes
8 Apr 22
Prospectus supplement
9:45pm
10-K
iya7dpph 8a
8 Apr 22
Annual report
9:14pm